Mone Zaidi, MD, PhD, director of the Center for Translational Medicine and Pharmacology and Professor of Medicine, and Pharmacological Sciences, at the Icahn School of Medicine at Mount Sinai, has been awarded the 2022 International Research Prize from the Austrian Bone and Mineral Society , the largest medical association in Austria. The International Research Prize is the most coveted prize in bone and mineral research and is awarded once every three years.
Since its inception in 1988, the International Research Prize has been awarded to individuals whose recent work in molecular, cellular or material science, or the pathophysiological or clinical aspects of bone and mineral metabolism, has led to a new finding or concept.
An international jury independently selected Dr. Zaidi as the prize winner, and he received 7,500 euros ($8,000 USD) at the Osteoporosis Forum, the 30e annual meeting of the Austrian Bone and Mineral Society, which was held on June 23-25 in St. Wolfgang, Austria. The following pieces from Dr. Zaidi’s work was featured at this conference.
- Oxytocin regulates body composition. Proceedings of the National Academy of Sciences 116: 26808-26815.
- Premium humanized FSH blocking antibody targets bone and fat. Proceedings of the National Academy of Sciences 117: 28971-28979.
- FSH blockade improves cognition in mice with Alzheimer’s disease. Nature 603: 470-476.
“It is a truly humbling experience to receive this award and to be a part of this small group of celebrities in my field – something I could not have achieved without the exceptionally talented teachers and interns and distinguished collaborators with whom I have had the honor of to work with during these years,” said Dr. Zaidi.
dr. Zaidi has made groundbreaking discoveries about mechanisms of skeletal homeostasis in health and disease. Spanning more than 30 years, these studies include the first description of calcium detection in the osteoclast and the discovery that locally released nitric oxide suppresses bone cells. In 2003, the group of Dr. Zaidi provided the first evidence for a pituitary-bone axis, a breakthrough in physiology in which pituitary hormones could directly affect the skeleton. In recent groundbreaking articles in Nature, he found that inhibiting follicle-stimulating hormone (FSH) not only increased bone mass, but also decreased body fat and neurodegeneration — essentially laying a solid foundation for a single anti-FSH drug to treat osteoporosis. , obesity and Alzheimer’s disease.
The work on FSH with body fat was selected by Nature Medicine as one of eight “Remarkable Advances” in Biomedicine for 2017. Dr. Zaidi, with a total of more than 450 journal publications, is continuously funded by the National Institutes of Health (NIH). He has also chaired multiple departments of study for the NIH and the Department of Veterans Affairs. He was president of the Interurban Clinical Club and was elected a member of the Association of American Physicians, the Practitioners’ Society (the oldest medical association in the United States), and the Association of Professors of Medicine. dr. Zaidi is a Master of the American College of Physicians, received the Harrington Scholar-Innovator Award, was elected a Fellow of the American Association of Advancement of Science, and received three honorary degrees.
“Dr. Zaidi is an exceptional researcher who has made breakthrough discoveries throughout his career about the mechanisms of musculoskeletal homeostasis in health and disease,” said Eric J. Nestler, MD, PhD, Nash Family Professor of Neuroscience, Director of The Friedman Brain Institute, and Dean for Academic Affairs of Icahn Mount Sinai, and Chief Scientific Officer of the Mount Sinai Health System. “I congratulate Dr. Zaidi on receiving one of the most prestigious awards in his field and we are delighted to be recognized by the largest medical association in Austria.”
#Researcher #receives #prestigious #international #prize